Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, researchers observed hair regrowth in a patient with alopecia universalis and psoriasis after treatment with deucravacitinib, a TYK2 inhibitor, though they note spontaneous regrowth cannot be ruled out and suggest further controlled studies to evaluate its effects on alopecia areata.

This study identified three EDAR gene variants potentially linked to hypohidrotic ectodermal dysplasia in three Pakistani families, which could aid in genetic counseling for similar cases.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

This study developed a consensus document to guide danazol discontinuation in hereditary angioedema patients, enhancing the standardization and safety of treatment protocols.

This study reviews the therapeutic potential of Yashtimadhu (Glycyrrhiza glabra Linn.), highlighting its efficacy in managing diseases affecting the head and neck, based on a conceptual and analytical synthesis of Ayurvedic literature and contemporary scientific perspectives.

This study found that Yangxuebushen Decoction significantly promoted hair regrowth and improved hair follicle structure in a cyclophosphamide-induced alopecia mouse model by reducing inflammation, oxidative stress, and apoptosis.

This case study reports the first known instance of successful rapid hair regrowth in a psoriasis patient with alopecia universalis after starting deucravacitinib, suggesting potential for TYK2 inhibitors in managing alopecia areata.

This study reported that acupuncture combined with topical Aloe vera and celery gel reduced hair loss from alopecia androgenetica after 28 days of treatment.

In a case report, complete hair regrowth was observed in a patient with severe alopecia areata after treatment with deucravacitinib, a TYK2 inhibitor, suggesting new therapeutic avenues for alopecia areata despite TYK2 not being traditionally linked to this condition.

In this case study, a 26-year-old female with hair fall, dandruff, scalp itching, and dry hair reported improvements after using Dhatturadi Tail and taking Yashtimadhu churna with milk, evaluated through a custom scoring system, according to researchers at the National Institute of Ayurveda, Jaipur.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

This study found that yellow dots seen under dermatoscopy are a sensitive and specific indicator of treatment response in alopecia areata, showing significant reduction as early as four weeks.

This review reports on the potential for deucravacitinib, an oral TYK2 inhibitor approved for psoriasis, to treat various immune-mediated diseases, with emerging research suggesting possible uses in neurodegenerative diseases and certain cancers.

In this study, oral dutasteride treatment for at least 12 months was associated with either stabilization or improvement of male-pattern hair loss in the majority of patients.

In this study, UPA at doses of 15 mg and 30 mg showed higher efficacy than placebo for treating severe alopecia areata in adults and adolescents over 24 weeks, with a safety profile similar to approved uses.

This study found that non-daily use of Dutasteride may be more cost-effective and associated with lower cancer incidence than daily use for patients seeking treatment for lower urinary tract symptoms.

This study found that home-use diphenylcyclopropenone (H-DPCP) is a cost-effective alternative to office-use for severe alopecia areata, showing similar effectiveness with reduced costs.

This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

In this study, alopecia areata patients treated with diphencyprone showed a significant increase in CD8 lymphocytes around hair bulbs, which may be associated with hair regrowth.

This case report describes a 12-year-old girl's persistent and worsening scalp condition, ultimately diagnosed as pityriasis amiantacea secondary to localized Darier's disease, after numerous ineffective treatments.

Deuruxolitinib is generally safe for treating alopecia areata.

This case report describes a 54-year-old woman with familial dyskeratotic comedones who experienced slight improvement in her skin lesions after three months of treatment with topical retinoids and urea cream.

This study is collecting real-world data to evaluate abrocitinib and conventional systemic treatments in moderate-to-severe atopic dermatitis across five European registers over a three-year period.

Topical dapsone gel reduced flare-ups in folliculitis decalvans without side effects.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.